フィルグラスチム 化學特性,用途語,生産方法
外観
無色澄明の液體
説明
Filgrastim is a recombinant human granulocyte colony stimulating factor (G-CSF)
indicated as an adjunct to cancer chemotherapy for patients with non-myeloid
malignancies. It reduces the duration of chemotherapy-induced neutropenia by forcing
immature leucocytes to differentiate into neutrophils, thereby decreasing the incidence
and length of infections.Bone pain is the most significant side effect.Chugai
launched the second G-CSF, lenograstim, in December 1991. Other potential uses
include bone marrow transplants, myelodysplastic syndromes and febrilelchronic
neutropenia.
化學的特性
Clear, colourless or slightly yellowish liquid
使用
Filgrastim is a human granulocyte colony stimulating factor (G-CSF) used to treat neutropenia.
適応癥
Filgrastim (Neupogen) is a human recombinant granulocyte
colony–stimulating factor (rG-CSF) produced
using recombinant DNA technology. It acts on precursor
hematopoietic cells in the bone marrow by binding
to specific receptors that stimulate cellular proliferation
and differentiation into neutrophils. It also enhances
some neutrophil functions, including phagocytosis and
antibody-dependent killing.
臨床応用
Filgrastim, G-CSF, Neupogen, stimulates the proliferation ofgranulocytes (especially neutrophils) by mobilizinghematopoietic stem cells in the bone marrow. The native protein is glycosylated.Filgrastim selectively stimulates proliferation and differentiationof neutrophil precursors in the bone marrow. Thisleads to the release of mature neutrophils into the circulationfrom the bone marrow. Filgrastim also affects mature neutrophilsby enhancing phagocytic activity, priming the cellularmetabolic pathways associated with the respiratoryburst, enhancing antibody-dependent killing, and increasingthe expression of some functions associated with cell surfaceantigens.
In patients receiving chemotherapy with drugs such ascyclophosphamide, doxorubicin, and etoposide, the incidenceof neutropenia accompanied by fever is rather high.Administration of G-CSF reduces the time of neutrophilrecovery and duration of fever in adults with acute myelogenousleukemia. The number of infections, days thatantibiotics are required, and duration of hospitalization arealso reduced.
副作用
The drug is generally well tolerated, with the major
adverse reaction being mild to moderate bone pain secondary
to stimulation of bone marrow proliferation.
フィルグラスチム 上流と下流の製品情報
原材料
準備製品